vascuCAP vs CAC Software
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 70/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
Tool A (vascuCAP) provides a comprehensive analysis of plaque composition from CT angiography, including detailed characterization of various plaque components to support personalized treatment decisions and risk stratification for stroke and heart attack. Tool B (CAC Software) specializes in quantifying coronary artery calcification from non-contrast chest CTs, providing metrics like the Agatston score for coronary artery disease risk assessment. While both aid in cardiovascular risk assessment through CT analysis, vascuCAP offers a broader plaque characterization, whereas CAC Software focuses specifically on calcification.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
Elucid Bioimaging's vascuCAP (now ElucidVivo/PlaqueIQ) analyzes non-invasive CT angiography scans. Imbio's CAC Software is designed for non-contrast chest computed tomography (CT) scans.
vascuCAP quantifies lipid-rich necrotic core, calcification, non-calcified matrix, and intraplaque hemorrhage, providing histologically-validated plaque quantification and characterization. Imbio's CAC Software quantifies calcification within coronary arteries, outputting the Agatston score, arterial age, and calcified lesion mass and volume.
vascuCAP offers risk stratification for stroke and heart attack, supporting personalized treatment decisions. Imbio's CAC Software supports risk assessment specifically for coronary artery disease.
vascuCAP provides 3D visualization of arterial vessels and plaque. Imbio's CAC Software offers 3D visualizations and annotated images of calcification.
vascuCAP offers DICOM integration and PACS/EMR interoperability. Imbio's CAC Software integrates into existing DICOM viewing workflows.